genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Regulus Therapeutics
Drug Discovery
StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug
Insights
Clinical Application of miRNAs a Ways Off
Cancer
Regulus and UCSD Partner to Develop miRNA-Targeting Anti-Angiogenesis Therapeutics
News
Regulus Licenses miR-33a and miR-33b Therapeutic IP from NYU
Industry News
Sanofi-Aventis Invests $10M in Regulus
News
GSK and Regulus to Collaborate on miRNA-Based HCV Drugs
Industry News
Regulus Raises $20M in Series A Round
News
Regulus Licenses miRNA Antagonist IP from Stanford University
Infectious Diseases
Regulus Therapeutics and Duke Univ. Find that Viral miRNAs Mimic Human miRNAs
Scroll Up
Scroll Up
